EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Psilocybin as serotonergic therapy in epilepsy: Narrative review of potentials and limitations

Miguel Benjamin Cervera-Sanchez iD, Daniel San-Juan iD, Roberto Díaz-Peregrino iD, Evelin Zulema Camacho-Castillo iD, Sthefany Anahi Bringas-Ortiz iD, Christian Padilla-Cabezutd iD

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70690 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Miguel Benjamin Cervera-Sanchez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Epilepsy Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico. Hauptthemen laut MEDLINE: Psilocybin, Epilepsy, Anticonvulsants. Die Arbeit nennt 78 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psilocybin shows potential in neuropsychiatric disorders but has a complex relationship with epilepsy and seizures. We reviewed literature up to November 2025 to identify studies relevant to psilocybin's effects on seizures and epilepsy, including our research on serotonergic modulation. Core studies addressing the research question and supplementary mechanistic evidence were included for synthesis. Risk of bias (RoB) was assessed by study type; independent reviewers achieved strong agreement (unweighted Cohen's κ = 0.80, SE = 0.185; 99% CI 0.006–0.011; per cent agreement = 88.9%). Experimental models suggest psilocybin , through 5‐hydroxytryptamine receptor 2A ( 5-T2A ) activation, may confer antiseizure effects. Preclinical data support serotonergic modulation as a promising strategy. RoB assessment highlighted methodological challenges, suggesting cautious interpretation. Clinical evidence in neuropsychiatric populations shows no increased seizure risk under medical supervision. Psilocybin could serve as an adjunctive therapy via selective serotonergic modulation. However, conflicting evidence and concerns at high doses urge caution. Future animal studies and clinical trials must confirm psilocybin's safety and efficacy in the treatment of epilepsy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsilocybinEpilepsyAnticonvulsantsHumansAnimalsSerotonin 5-HT2 Receptor AgonistsHallucinogens

Stichwörter der Autor:innen

epilepsypsilocybinpsychedelicsserotonergic therapy

Substanzen

PsilocybinAnticonvulsantsSerotonin 5-HT2 Receptor AgonistsHallucinogens

Autor:innen und Institutionen

  • Epilepsy Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
  • Department of Neurosurgery, Heidelberg University Hospital, Ruprecht Karls University of Heidelberg, Heidelberg, Germany.
  • Autonomous University of Mexico State, Toluca, Mexico.
  • University Center for Health Science, University of Guadalajara, Guadalajara, Mexico.

ORCID-Profile: Miguel Benjamin Cervera-Sanchez, Daniel San-Juan, Roberto Díaz-Peregrino, Evelin Zulema Camacho-Castillo, Sthefany Anahi Bringas-Ortiz, Christian Padilla-Cabezutd

Zitieren

APA

Cervera-Sanchez, M. B., San-Juan, D., Díaz-Peregrino, R., Camacho-Castillo, E. Z., Bringas-Ortiz, S. A., & Padilla-Cabezutd, C. (2026). Psilocybin as serotonergic therapy in epilepsy: Narrative review of potentials and limitations. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70690

Vancouver

Cervera-Sanchez MB, San-Juan D, Díaz-Peregrino R, Camacho-Castillo EZ, Bringas-Ortiz SA, Padilla-Cabezutd C. Psilocybin as serotonergic therapy in epilepsy: Narrative review of potentials and limitations. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70690

BibTeX
@article{CerveraSanchez2026,
  author = {Cervera-Sanchez, Miguel Benjamin and San-Juan, Daniel and Díaz-Peregrino, Roberto and Camacho-Castillo, Evelin Zulema and Bringas-Ortiz, Sthefany Anahi and Padilla-Cabezutd, Christian},
  title = {Psilocybin as serotonergic therapy in epilepsy: Narrative review of potentials and limitations},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70690}
}
Kostenlos starten →